Skip to main content
Log in

Cost—Utility Analysis of Early Thrombolytic Therapy

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

167 patients suffering from acute myocardial infarction (AMI) were recruited from 12 cardiology centres and given thrombolytic treatment. Cost—utility analyses were performed and a cost—utility ratio was computed according to time of initiation of thrombolysis after the AMI and the location of the infarct. Early thrombolysis (< 3 hours) proved to cost about the same per QALY ($US3734 vs $US3577) as late thrombolysis (> 3 hours), although posterior infarcts cost slightly more per QALY ($3433 vs $2996) than anterior infarcts. Quality of life coefficients for all patients after the AMI were judged to be about 40% less than before the AMI. Thus, in terms of resources consumed and patient well—being, time of treatment initiation or location of the infarct were less significant than the fact of having an AMI. In terms of quality of life, the best strategy is that which seeks to prevent AMI occurring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • AIMS. The APSAC Intervention Mortality Study. Effects of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo—controlled clinical trial. Lancet 1: 545–549, 1988

    Google Scholar 

  • Castiel D. L’analyse coût—avantage: critère de choix des investissements médicaux et stratègies thérapeutiques? Application à la thrombolyse précoce dans la prise en charge des malades coronariens. Thèse pour Ie Doctorat ès Sciences Economiques, Universite Paris XII, Créteil, 1991

    Google Scholar 

  • Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, Chapter 6, pp. 112–148, Oxford University Press, Oxford, 1987

    Google Scholar 

  • Ganiats T, Schneidermann L. Principles of cost—effectiveness research. Journal of Family Practice 27: 77–84, 1988

    PubMed  CAS  Google Scholar 

  • Fletcher AE, Bulpitt CJ. Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective. PharmacoEconomics 1: 33–44, 1992

    Article  PubMed  CAS  Google Scholar 

  • GISSI. Gruppo Italiano per Ie studio della streptokinase nell’infarcto miocardico. Long term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 2: 871–874, 1987

    Google Scholar 

  • Hervé C, Castiel D, Gaillard M, Daussac C, Leroux V. Implications socioeconomiques de la pratique de la thrombolyse a la phase aigue de l’infarctus du myocarde. Archives des Maladies du Coeur et des Vaisseaux 82: 353–358, 1989

    PubMed  Google Scholar 

  • Hervé C, Castiel D, Gaillard M, Boisvert R, Leroux V. Costbenefit analysis of thrombolytic therapy. European Heart Journal 11: 1006–1010, 1990

    PubMed  Google Scholar 

  • Hervé C, Castiel D, Gaillard M, Leroux V. Methode d’evaluation de la qualite de vie apres infarctus du myocarde. Presse Medicale 20: 1623, 1991

    Google Scholar 

  • ISIS 2. Second Internationa Study of Infarct Survival. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction. Lancet 2: 349–360, 1988

    Google Scholar 

  • Li M. A logit model of homeownership. Econometrica 7: 1081–1096, 1977

    Article  Google Scholar 

  • Maddala GS. Econometrics, Chapter 9: Dummy variables and nonlinearities in multiole regression, pp. 163–171, McGrawHill, Singapore, 1987

    Google Scholar 

  • Pell S, Fayerweather W. Trends in the incidence of myocardial infarction, and in associated mortality and morbidity in a large employed population, 1957–1983. New England Journal of Medicine 312: 1005–1011, 1985

    Article  PubMed  CAS  Google Scholar 

  • Stason WB. Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol. American Heart Journal 119: 718–724, 1990

    Article  PubMed  CAS  Google Scholar 

  • Vermeer F, Maarten L, Simoons M, de Zwoon C, van Es GA, et al. Cost—benefit analysis of early thrombolytic treatment with intracoronary streptokinase. British Heart Journal 59: 527–534, 1988

    Article  PubMed  CAS  Google Scholar 

  • Weinstein MC, Stason WB. Foundations of cost—effectiveness analysis for health and medical practices. New England Journal of Medicine 296: 716–721, 1977

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castiel, D., Hervé, C., Gaillard, M. et al. Cost—Utility Analysis of Early Thrombolytic Therapy. Pharmacoeconomics 1, 438–442 (1992). https://doi.org/10.2165/00019053-199201060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199201060-00004

Keywords

Navigation